Our primary focus in clinical trials is the prevention of cerebral edema, testing the hypothesis that the sulfonylurea receptor 1 (Sur1) mediates edema formation after stroke. The clinical development of the Sur1 inhibitor, intravenous glyburide, began with a Phase 2a pilot clinical trial (GAMES-Pilot Trial), which evaluated the safety and efficacy for the prevention of […]
We develop novel neuroimaging tools to better quantify brain edema and blood-brain barrier integrity in the setting of cerebral ischemia. By creating high specificity methods using non-invasive imaging, we have advanced our understanding of the role brain edema plays in modulating neurological recovery after stroke. These studies have revealed that brain edema may impact recovery in […]
A major tool we use is metabolite profiling (“metabolomics”), a liquid chromatography-tandem mass spectrometry (LC-MS/MS) technique that measures >200 metabolites simultaneously. We have used this approach to study the acute stress hyperglycemia response after stroke, discovering a link between hyperglycemia, brain cytotoxic injury and subsequent brain edema formation. We have also applied the technique to […]
Although inflammation after ischemic stroke is a well-described phenomenon and hypothesized to play a key role in secondary injury, the underlying mechanisms are not well understood. We have identified soluble ST2 as an inflammatory biomarker that is elevated following acute ischemic stroke. Our studies have highlighted that soluble ST2 predicts functional outcome, mortality and risk […]
